Diabetic Foot Ulcer Clinical Trial
Official title:
A Randomised, Controlled, Phase 1 Study to Investigate Safety, Tolerability and Efficacy of CYP-006TK in Adults With Diabetic Foot Ulcers
Verified date | May 2024 |
Source | Cynata Therapeutics Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Design: A randomised, controlled, prospective trial. Participants will be patients with non-healing diabetic foot ulcers. The study will aim to recruit 15 participants per study group (30 participants in total). Participants will be randomly allocated to one of two treatment groups: - Group 1: CYP-006TK - Group 2: Standard care This will be an open label study with respect to treatment allocation. However, the person reviewing images of the study ulcers to assess healing will be blind to the participant's treatment allocation. Participants assigned to Group 1 will be treated with CYP-0006TK dressings on 8 occasions over 4 weeks. The dressings will be changed every 3 or 4 days. After the first 4 weeks, participants in Group 1 will revert to standard care for the rest of the study. Participants assigned to Group 2 will have their ulcer treated with standard care throughout the study. Participants will attend a total of 16 scheduled visits over 24 weeks. There will be a mixture of on-site (hospital/clinic) visits, and home visits. The study will end 24 weeks after the initiation of treatment, unless the study ulcer is completely headed before then.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | September 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adults at least 18 years of age up to 80 years of age, inclusive. 2. Have a current diagnosis of diabetes mellitus (DM) 3. With at least one non-healing cutaneous ulcer on the foot or the lower legs 4. With ankle brachial index (ABI) = 0.4 and/or toe pressure >30 mmHg on the limb with the study ulcer. 5. Participant co-morbidities are adequately managed, and the participant has a life expectancy of at least 6 months as determined by the Investigator based on medical history, physical examination, vital signs, or clinical laboratory tests, etc. 6. A negative pregnancy test, (i.e. for female participants with childbearing potential). 7. Willing to comply with birth control measures, to prevent female participants becoming pregnant for six months following administration of the study treatment. 8. Able to follow the Investigator's instruction on ulcer care (in the opinion of the Investigator). 9. Agrees to provide written informed consent. Exclusion Criteria: 1. Planned vascular surgery, angioplasty, thrombolysis or amputation of the affected limb in the next six months. 2. Pregnant or breastfeeding. 3. Active infection in the study ulcer. 4. Any sign of osteomyelitis associated with the study ulcer. 5. Study ulcer extends to bone or periosteum (ulcers that reach a ligament, joint capsule, fascia, or tendon are not excluded). 6. Study ulcer requires daily dressing changes. 7. Known autoimmune disease other than diabetes, including but not limited to lupus erythematosus, multiple sclerosis which are considered as clinically significant by PI and/or Medical Monitor. 8. Treatment with systemic immunosuppressants within 90 days of screening. 9. Active malignancy or history of malignancy within five years prior to screening (with the exception of a past history of basal or squamous cell carcinomas). 10. Serum GGT, AST or ALT > 5 × upper limit of the normal range (ULN). 11. . Known history of HIV infection 12. Prior administration of any cell-based treatment to the limb affected by the study ulcer. 13. Received any investigational research agent within 60 days or within five half-lives of the last treatment (if the half-life of the investigational agent is known to be longer than 12 days) prior to the planned initiation of study treatment. 14. Any other medical condition or laboratory abnormality judged as clinically significant by the Investigator or study Medical Monitor which could confound the evaluation of the trial treatment. 15. With history of sensitivity to materials of bovine, porcine origin, or human serum albumin. |
Country | Name | City | State |
---|---|---|---|
Australia | Central Adelaide Local Health Network | Adelaide | South Australia |
Australia | Fiona Stanley Hospital | Perth | Western Australia |
Australia | Royal Perth Hospital | Perth | Western Australia |
Australia | Sir Charles Gairdner Hospital | Perth | Western Australia |
Lead Sponsor | Collaborator |
---|---|
Cynata Therapeutics Limited |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence and severity of treatment-emergent adverse events (TEAEs) | 24 weeks | ||
Primary | Incidence of changes from baseline in haematology, biochemistry, and urinalysis parameters. | Results will be summarised by individual and by treatment group using descriptive statistics. | 24 weeks | |
Secondary | Percentage of area change of study ulcer from baseline to weeks 12 and 24 | 12 and 24 weeks | ||
Secondary | Number of days to complete ulcer healing | 12 and 24 weeks | ||
Secondary | Number of days to 50% ulcer healing | 12 and 24 weeks | ||
Secondary | Percentage change in ulcer volume from baseline to weeks 12 and 24 | 12 and 24 weeks | ||
Secondary | Changes from baseline in ulcer pain assessed using a Numeric Rating Scale | 12 and 24 weeks | ||
Secondary | Number clinic/home care visits across groups | 12 and 24 weeks | ||
Secondary | Differences across groups on ulcer dressing products used | 12 and 24 weeks | ||
Secondary | Changes from baseline in Quality of Life assessed using the Cardiff Wound Impact Schedule | 12 and 24 weeks | ||
Secondary | Duration of clinic/home care visits across groups | 12 and 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04497805 -
Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers
|
Phase 2 | |
Withdrawn |
NCT03675269 -
Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer:
|
N/A | |
Completed |
NCT04624516 -
Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence
|
N/A | |
Not yet recruiting |
NCT06439667 -
VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
|
||
Recruiting |
NCT05608187 -
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
|
Phase 2 | |
Not yet recruiting |
NCT06278935 -
Lifestyle Tailored Offloading for Diabetic Foot Ulcers
|
N/A | |
Not yet recruiting |
NCT06437028 -
Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers.
|
N/A | |
Withdrawn |
NCT05024656 -
AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT02202668 -
Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT01966380 -
Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia
|
Phase 2 | |
Completed |
NCT01951768 -
Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection
|
Phase 4 | |
Completed |
NCT01657474 -
Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers
|
N/A | |
Active, not recruiting |
NCT00389636 -
TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01181440 -
Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers
|
Phase 3 | |
Enrolling by invitation |
NCT05888259 -
Plantar Pressure Distribution in Diabetic Foot Ulcer
|
N/A | |
Completed |
NCT04054804 -
Digital Foot Check by Using the D-Foot, a New Software
|
||
Not yet recruiting |
NCT05877378 -
Efficacy of PICO Single-use System in Chronic Ulcers
|
N/A | |
Recruiting |
NCT06037369 -
The Short Message-based Customized Standardized
|
N/A | |
Completed |
NCT03312595 -
Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
|
N/A | |
Recruiting |
NCT04564443 -
A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot
|
N/A |